Bristol Myers and Janssen race toward PhIII with a next-gen blood thinner

Bristol Myers Squibb and J&J joined forces three years ago with a vision: They wanted to create a blood thinner with the efficacy of their current drugs Eliquis and Xarelto, but without the heightened risk of bleeding.

On Monday, they announced they’re well on their way with a Factor XIa inhibitor called milvexian.